Non-allogeneic immunotherapy in acute myeloid leukaemia.
The Lancet Haematology(2019)
摘要
Over the past thirty years, substantial progress has been made in understanding the pathophysiology of acute myeloid leukaemia, leading to better therapeutic strategies and substantial improvement in the treatment outcome. 1 Kantarjian H Acute myeloid leukaemia—major progress over four decades and glimpses into the future. Am J Hematol. 2016; 91: 131-145 Crossref PubMed Scopus (81) Google Scholar Nevertheless, treatment for young patients is often still based on stem-cell transplantation preceded by intensive chemotherapy, to which new molecules are sometimes added, such as gemtuzumab ozogamicin 2 Castaigne S Pautas C Terré C et al. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet. 2012; 379: 1508-1516 Summary Full Text Full Text PDF PubMed Scopus (690) Google Scholar or FLT3 inhibitors, 3 Stone RM Mandrekar SJ Sanford BL et al. Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation. N Engl J Med. 2017; 377: 454-464 Crossref PubMed Scopus (1207) Google Scholar two approved drugs in this setting. Idarubicin, cytarabine, and nivolumab in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome: a single-arm, phase 2 studyAddition of nivolumab to induction chemotherapy with idarubicin and cytarabine is feasible in patients with newly diagnosed acute myeloid leukaemia or high-risk myelodysplastic syndrome. Post-transplant severe graft-versus-host disease could be improved, and earlier initiation of checkpoint inhibitor therapy is warranted in future studies. Full-Text PDF
更多查看译文
关键词
acute myeloid,non-allogeneic
AI 理解论文
溯源树
样例
生成溯源树,研究论文发展脉络